CannPal Animal Therapeutics R&D research to be published in leading veterinary journal
CannPal Animal Therapeutics Ltd (ASX:CP1) is being recognised for its robust and leading research into medicinal cannabis treatments for animals through participation in Australia’s largest veterinary conference and publication of its first research abstract.
This will provide the company the opportunity to directly present to 1,400 veterinarians at the Australian Veterinary Association (AVA) Innovation, Research and Development Symposium in May.
CannPal will also reach more than 5,000 through publication of its abstract in the Australian Veterinary Journal (AVJ), which is Australia’s premier veterinary scientific journal.
Founder and managing director Layton Mills said the presentation and AVJ publication was a significant milestone for the company.
He said: “There is significant demand from pet owners for cannabinoid-derived therapeutics, but veterinarians don’t yet have a thought leader providing them with reliable data or regulatory approved products.
“The AVJ publication is the first step in CannPal establishing ourselves as the provider of that data, and hopefully of regulatory approved, safe and effective veterinary medicines”.
“Building a trusting relationship” with vets
“This is an important step in building a trusting relationship with vets as we get closer towards commercialising our products through various regulatory pathways.”
During the AVA Innovation Symposium in Perth next month CannPal’s head of R&D Dr Margaret Curtis will present on the company’s Phase 1 trial results.
This will include the pharmacokinetic, safety, gene expression and inflammatory biomarker results from the robust randomised three group parallel pharmacokinetic study completed in 2018.
READ: CannPal Animal Therapeutics receives approvals for two clinical studies
The AVA event between May 5 and 10 is the largest veterinary conference in Australia, with an average of 1,400 veterinary professionals expected to attend.
It is a platform for industry and animal researchers to present their clinical research and findings directly to the veterinary profession.
The Innovation Symposium will be on Sunday, May 5, and Dr Curtis will present at 3.35pm alongside speakers from world-leading animal health companies such as Bayer, Ceva and Virbac.
Abstracts from the symposium will be published in the AVJ, which is Australia’s premier veterinary scientific journal, reaching an audience of over 5,000 AVA members.
CannPal generates “exciting results”
Dr Curtis said: “This is a great opportunity to get our initial results out into the veterinary fraternity in Australia.
“The AVJ is widely read, and publication of this work will further disseminate the exciting results that CannPal is generating, bringing us closer to potentially approvable cannabis-derived medicines for pets.”
MD Mills said: “Since founding the company, CannPal has placed diligent focus on building a credible and experienced R&D team to complete robust and world leading research on the safety and efficacy of cannabis-derived compounds for companion animals.
“The AVA Symposium is an opportunity for CannPal to start sharing some of that research with the scientific and veterinary community, in the hopes of establishing CannPal as a clear leader in this field.”
READ: CannPal Animal Therapeutics director buys 100,000 shares on-market
CannPal is researching and developing medicines derived from cannabinoids with the aim of providing veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/218804/cannpal-animal-therapeutics-rd-research-to-be-published-in-leading-veterinary-journal-218804.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).